Universal Beteiligungs und Servicegesellschaft mbH Purchases 131,320 Shares of Embecta Corp. $EMBC

Universal Beteiligungs und Servicegesellschaft mbH grew its position in Embecta Corp. (NASDAQ:EMBC) by 1,068.0% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 143,616 shares of the company’s stock after buying an additional 131,320 shares during the period. Universal Beteiligungs und Servicegesellschaft mbH owned approximately 0.24% of Embecta worth $1,708,000 at the end of the most recent quarter.

Other hedge funds have also added to or reduced their stakes in the company. Larson Financial Group LLC lifted its holdings in Embecta by 368.6% during the third quarter. Larson Financial Group LLC now owns 2,001 shares of the company’s stock worth $28,000 after acquiring an additional 1,574 shares in the last quarter. Tower Research Capital LLC TRC increased its holdings in shares of Embecta by 542.6% in the second quarter. Tower Research Capital LLC TRC now owns 7,371 shares of the company’s stock worth $71,000 after acquiring an additional 6,224 shares in the last quarter. Wexford Capital LP bought a new stake in shares of Embecta in the third quarter worth about $94,000. Humankind Investments LLC acquired a new stake in shares of Embecta during the second quarter worth about $111,000. Finally, iSAM Funds UK Ltd acquired a new stake in shares of Embecta during the third quarter worth about $115,000. Institutional investors and hedge funds own 93.83% of the company’s stock.

Embecta Stock Up 0.9%

NASDAQ:EMBC opened at $9.23 on Friday. The company has a market cap of $546.60 million, a P/E ratio of 3.89 and a beta of 1.09. Embecta Corp. has a twelve month low of $8.47 and a twelve month high of $15.55. The business has a 50 day moving average price of $9.26 and a two-hundred day moving average price of $11.30.

Embecta (NASDAQ:EMBC) last posted its quarterly earnings data on Thursday, February 5th. The company reported $0.71 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.67 by $0.04. Embecta had a net margin of 12.92% and a negative return on equity of 26.66%. The company had revenue of $261.20 million for the quarter, compared to the consensus estimate of $258.07 million. During the same period last year, the company earned $0.65 earnings per share. The firm’s revenue was down .3% compared to the same quarter last year. Embecta has set its FY 2026 guidance at 2.800-3.00 EPS. As a group, analysts anticipate that Embecta Corp. will post 2.82 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on EMBC shares. Weiss Ratings reiterated a “hold (c-)” rating on shares of Embecta in a research report on Wednesday, January 21st. Mizuho dropped their target price on shares of Embecta from $14.00 to $12.00 and set a “neutral” rating on the stock in a report on Monday, April 13th. BTIG Research reaffirmed a “buy” rating and issued a $25.00 price target on shares of Embecta in a research note on Friday, February 6th. Finally, Wall Street Zen upgraded shares of Embecta from a “buy” rating to a “strong-buy” rating in a report on Saturday, March 7th. One analyst has rated the stock with a Buy rating and three have issued a Hold rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $18.50.

Embecta Profile

Embecta Corp (NASDAQ: EMBC) is a pure-play diabetes care company that was spun off from Becton, Dickinson and Company on July 1, 2021. Headquartered in Franklin Lakes, New Jersey, Embecta focuses exclusively on the development, manufacturing and commercialization of products that enable insulin delivery and blood glucose monitoring for people with diabetes.

The company’s product portfolio includes insulin infusion sets, durable and patch pumps, pen needles, infusion tubing, blood glucose test strips, lancets and lancing devices.